Symbols / IXHL $3.33 +0.45%
IXHL Chart
About
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 46.46M |
| Enterprise Value | -29.20M | Income | -48.50M | Sales | — |
| Book/sh | 6.13 | Cash/sh | 5.77 | Dividend Yield | — |
| Payout | 0.00% | Employees | 12 | IPO | — |
| P/E | — | Forward P/E | -1.70 | PEG | — |
| P/S | inf | P/B | 0.54 | P/C | — |
| EV/EBITDA | 1.15 | EV/Sales | — | Quick Ratio | 47.96 |
| Current Ratio | 48.27 | Debt/Eq | 0.22 | LT Debt/Eq | — |
| EPS (ttm) | -22.20 | EPS next Y | -1.96 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-13 07:00 | ROA | -36.96% |
| ROE | -130.43% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 13.97M |
| Shs Float | 10.69M | Short Float | 7.15% | Short Ratio | 2.68 |
| Short Interest | — | 52W High | 49.80 | 52W Low | 2.40 |
| Beta | 2.68 | Avg Volume | 428.63K | Volume | 309.55K |
| Target Price | — | Recom | None | Prev Close | $3.31 |
| Price | $3.33 | Change | 0.45% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$3.31
Latest analyst target
3. DCF / Fair value
$-12.13
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.31
Low
—
High
—
Mean
—
- Biotech Incannex clears Nasdaq listing hurdle, holds $75M cash and no debt - Stock Titan ue, 17 Mar 2026 12
- Incannex Healthcare (NASDAQ: IXHL) restores Nasdaq bid price compliance, highlights $75M cash - Stock Titan ue, 17 Mar 2026 12
- IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms - Stocktwits hu, 12 Mar 2026 07
- IXHL Stock Price, Quote & Chart | INCANNEX HEALTHCARE INC (NASDAQ:IXHL) - ChartMill Fri, 13 Mar 2026 07
- Incannex Regains Nasdaq Compliance, Strengthening Pipeline Progress - TipRanks ue, 17 Mar 2026 12
- Market Movers | Winners: AGRZ, EONR, TLYS | Losers: IXHL, AIV, NOA - Trefis Fri, 13 Mar 2026 08
- Incannex Healthcare Inc. (IXHL) Implements 1-for-30 Reverse Split Effective February 26 - Yahoo Finance ue, 03 Mar 2026 08
- Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement - marketscreener.com ue, 17 Mar 2026 12
- Incannex Healthcare (NASDAQ:IXHL) Stock Price Down 11% - What's Next? - MarketBeat Fri, 27 Feb 2026 08
- Why Did IXHL Stock Slump 35% Today? - Stocktwits hu, 12 Mar 2026 13
- Sleep apnea pill from Incannex cut apnea events by up to 83% in trial - Stock Titan hu, 12 Mar 2026 12
- What Makes Incannex Healthcare Inc. (IXHL) a New Buy Stock - Yahoo Finance Mon, 01 Dec 2025 08
- Incannex Healthcare Announces 1-for-30 Reverse Stock Split - TipRanks Wed, 25 Feb 2026 08
- Incannex regains compliance with Nasdaq minimum bid price requirement - marketscreener.com ue, 17 Mar 2026 12
- Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Update - MarketBeat Wed, 11 Mar 2026 03
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 22608692 | — | — | Stock Award(Grant) at price 0.00 per share. | LATHAM JOEL | Chief Executive Officer | — | 2025-11-14 00:00:00 | D |
| 1 | 1686956 | — | — | Stock Award(Grant) at price 0.00 per share. | ANASTASSOV GEORGE | Director | — | 2025-11-14 00:00:00 | D |
| 2 | 11302608 | — | — | Stock Award(Grant) at price 0.00 per share. | VALENTINE TROY ROBERT | Director | — | 2025-11-14 00:00:00 | D |
| 3 | 869565 | — | — | Stock Award(Grant) at price 0.00 per share. | SWAN JOSEPH | Chief Financial Officer | — | 2025-11-14 00:00:00 | D |
| 4 | 1686956 | — | — | Stock Award(Grant) at price 0.00 per share. | SWAN JOSEPH | Director | — | 2025-11-14 00:00:00 | D |
| 5 | 1686956 | — | — | Stock Award(Grant) at price 0.00 per share. | WIDDOWS PETER | Director | — | 2025-11-14 00:00:00 | D |
| 6 | 100476 | — | — | Stock Award(Grant) at price 0.00 per share. | SWAN JOSEPH | Officer | — | 2024-10-23 00:00:00 | D |
| 7 | 50793 | — | — | Stock Award(Grant) at price 0.00 per share. | SWAN JOSEPH | Chief Financial Officer | — | 2024-05-06 00:00:00 | D |
Financials
| Line Item | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -8.40K | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.30 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -22.65M | -18.30M | 21.86M | -10.07M |
| TotalUnusualItems | -23.69M | -28.00K | -35.41M | -92.61K |
| TotalUnusualItemsExcludingGoodwill | -23.69M | -28.00K | -35.41M | -92.61K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -18.46M | -48.81M | -10.25M | -8.54M |
| ReconciledDepreciation | 103.00K | 88.00K | 0.00 | 0.00 |
| ReconciledCostOfRevenue | 0.00 | 4.36K | 685.20K | |
| EBITDA | -18.33M | -13.55M | -10.16M | -8.57M |
| EBIT | -18.43M | -13.64M | -10.16M | -8.57M |
| NetInterestIncome | 206.00K | 241.00K | 4.31K | 2.01K |
| InterestIncome | 206.00K | 241.00K | 4.31K | 2.01K |
| NormalizedIncome | -23.20M | -18.44M | -13.40M | -10.16M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -18.46M | -48.81M | -10.25M | -8.54M |
| TotalExpenses | 18.62M | 13.64M | 10.16M | 10.00M |
| RentExpenseSupplemental | 348.00K | 84.00K | 77.28K | 87.03K |
| TotalOperatingIncomeAsReported | -30.04M | -49.67M | ||
| DilutedAverageShares | 1.15M | 538.81K | 529.00K | 9.93M |
| BasicAverageShares | 1.15M | 538.81K | 529.00K | 9.93M |
| DilutedEPS | -40.50 | -34.50 | -1.03 | -1.03 |
| BasicEPS | -40.50 | -34.50 | -1.03 | -1.03 |
| DilutedNIAvailtoComStockholders | -18.46M | -48.81M | -10.25M | -8.54M |
| NetIncomeCommonStockholders | -18.46M | -48.81M | -10.25M | -8.54M |
| NetIncome | -18.46M | -48.81M | -10.25M | -8.54M |
| NetIncomeIncludingNoncontrollingInterests | -18.46M | -48.81M | -10.25M | -8.54M |
| NetIncomeContinuousOperations | -18.46M | -48.81M | -10.25M | -8.54M |
| TaxProvision | 30.00K | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -18.43M | -48.81M | -10.25M | -8.54M |
| OtherIncomeExpense | -28.00K | -35.41M | -92.61K | 26.72K |
| OtherNonOperatingIncomeExpenses | -796.00K | 1.38M | 788.65K | 26.72K |
| SpecialIncomeCharges | 0.00 | -35.35M | -92.61K | 0.00 |
| OtherSpecialCharges | 35.35M | |||
| WriteOff | 0.00 | 92.61K | 0.00 | |
| GainOnSaleOfSecurity | -22.21M | -28.00K | -67.00K | |
| NetNonOperatingInterestIncomeExpense | 206.00K | 241.00K | 4.31K | 2.01K |
| InterestIncomeNonOperating | 206.00K | 241.00K | 4.31K | 2.01K |
| OperatingIncome | -18.61M | -13.64M | -10.16M | -8.57M |
| OperatingExpense | 18.62M | 13.64M | 10.16M | 9.31M |
| OtherOperatingExpenses | -11.43M | -683.00K | -28.18K | |
| OtherTaxes | -671.12K | -538.21K | 0.00 | |
| DepreciationAmortizationDepletionIncomeStatement | 103.00K | 88.00K | 0.00 | |
| DepreciationAndAmortizationInIncomeStatement | 103.00K | 88.00K | 0.00 | |
| DepreciationIncomeStatement | 103.00K | 88.00K | 0.00 | |
| ResearchAndDevelopment | 12.88M | 6.31M | 3.70M | 3.57M |
| SellingGeneralAndAdministration | 17.07M | 7.92M | 7.00M | 5.77M |
| SellingAndMarketingExpense | 1.05M | 1.25M | 1.89M | 3.27M |
| GeneralAndAdministrativeExpense | 16.02M | 6.67M | 5.11M | 2.51M |
| OtherGandA | 3.93M | 2.09M | 2.64M | 996.53K |
| RentAndLandingFees | 348.00K | 84.00K | 77.28K | 87.03K |
| SalariesAndWages | 11.74M | 4.50M | 2.39M | 1.42M |
| GrossProfit | 0.00 | -4.36K | 740.54K | |
| CostOfRevenue | 0.00 | 4.36K | 685.20K | |
| TotalRevenue | 12.00K | 0.00 | 0.00 | 1.43M |
| OperatingRevenue | 12.00K | 0.00 | 0.00 | 1.43M |
| Line Item | 2023-06-30 | 2022-06-30 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | 0.00 | ||
| OrdinarySharesNumber | 6.48M | 588.09K | 529.00K | 430.78K |
| ShareIssued | 6.48M | 588.09K | 529.00K | 430.78K |
| TotalDebt | 373.00K | 521.00K | 0.00 | |
| TangibleBookValue | 11.22M | 20.82M | 24.67M | 6.44M |
| InvestedCapital | 11.22M | 20.82M | 24.67M | 6.44M |
| WorkingCapital | 10.58M | 20.45M | 24.67M | 6.44M |
| NetTangibleAssets | 11.22M | 20.82M | 24.67M | 6.44M |
| CapitalLeaseObligations | 373.00K | 521.00K | 0.00 | |
| CommonStockEquity | 11.22M | 20.82M | 24.67M | 6.44M |
| TotalCapitalization | 11.22M | 20.82M | 24.67M | 6.44M |
| TotalEquityGrossMinorityInterest | 11.22M | 20.82M | 24.67M | 6.44M |
| StockholdersEquity | 11.22M | 20.82M | 24.67M | 6.44M |
| OtherEquityInterest | 7.98M | 5.56M | 4.97M | |
| GainsLossesNotAffectingRetainedEarnings | -3.33M | -3.25M | 3.32M | |
| OtherEquityAdjustments | 3.32M | |||
| ForeignCurrencyTranslationAdjustments | -3.33M | -3.25M | ||
| RetainedEarnings | -110.67M | -92.21M | -40.45M | -32.98M |
| AdditionalPaidInCapital | 125.22M | 116.29M | ||
| CapitalStock | 2.00K | 2.00K | 59.56M | 34.45M |
| CommonStock | 2.00K | 2.00K | 59.56M | 34.45M |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 5.83M | 2.96M | 1.38M | 567.30K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 210.00K | 408.00K | 0.00 | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 210.00K | 408.00K | 0.00 | |
| LongTermCapitalLeaseObligation | 210.00K | 408.00K | 0.00 | |
| CurrentLiabilities | 5.62M | 2.55M | 1.38M | 567.30K |
| CurrentDeferredLiabilities | 85.00K | 0.00 | ||
| CurrentDeferredRevenue | 85.00K | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 163.00K | 113.00K | ||
| CurrentCapitalLeaseObligation | 163.00K | 113.00K | 0.00 | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 333.00K | 263.00K | 202.51K | 105.35K |
| PayablesAndAccruedExpenses | 5.04M | 2.17M | 1.18M | 461.95K |
| CurrentAccruedExpenses | 4.51M | 426.00K | 285.79K | 286.80K |
| Payables | 527.00K | 1.75M | 894.76K | 175.15K |
| OtherPayable | 521.93K | |||
| AccountsPayable | 527.00K | 1.75M | 894.76K | 175.15K |
| TotalAssets | 17.05M | 23.78M | 26.06M | 7.01M |
| TotalNonCurrentAssets | 845.00K | 786.00K | 0.00 | 0.00 |
| GoodwillAndOtherIntangibleAssets | 34.90M | 0.00 | ||
| NetPPE | 845.00K | 786.00K | 0.00 | |
| AccumulatedDepreciation | -126.00K | -23.00K | ||
| GrossPPE | 971.00K | 809.00K | 0.00 | |
| ConstructionInProgress | 0.00 | 160.00K | ||
| OtherProperties | 1.19M | |||
| MachineryFurnitureEquipment | 598.00K | 157.00K | ||
| BuildingsAndImprovements | 373.00K | 492.00K | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 16.20M | 23.00M | 26.06M | 7.01M |
| OtherCurrentAssets | 1.04M | |||
| PrepaidAssets | 329.00K | 686.00K | 41.16K | 27.12K |
| Receivables | 10.02M | 191.00K | 219.33K | 127.04K |
| OtherReceivables | 40.16K | |||
| TaxesReceivable | 10.02M | 191.00K | 202.74K | 86.89K |
| NotesReceivable | 66.20K | 16.60K | 0.00 | |
| AccountsReceivable | 287.48K | 53.45K | ||
| GrossAccountsReceivable | 53.45K | |||
| CashCashEquivalentsAndShortTermInvestments | 5.86M | 22.12M | 25.80M | 6.85M |
| CashAndCashEquivalents | 5.86M | 22.12M | 25.80M | 6.85M |
| CashFinancial | 22.08M | 25.80M | 6.85M |
| Line Item | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -16.12M | -11.06M | -8.81M | -5.19M |
| RepaymentOfDebt | -36.22K | 0.00 | ||
| IssuanceOfCapitalStock | 0.00 | 8.18M | 28.33M | 9.32M |
| CapitalExpenditure | -277.00K | -316.00K | ||
| EndCashPosition | 5.86M | 22.12M | 25.80M | 6.85M |
| BeginningCashPosition | 22.12M | 25.83M | 6.28M | 2.71M |
| EffectOfExchangeRateChanges | -140.00K | -824.00K | 0.00 | 0.00 |
| ChangesInCash | -16.12M | -2.89M | 19.52M | 4.15M |
| FinancingCashFlow | 0.00 | 8.18M | 28.33M | 9.32M |
| CashFlowFromContinuingFinancingActivities | 0.00 | 8.18M | 28.33M | 9.32M |
| NetCommonStockIssuance | 0.00 | 8.18M | 28.33M | 9.32M |
| CommonStockIssuance | 0.00 | 8.18M | 28.33M | 9.32M |
| NetIssuancePaymentsOfDebt | -36.22K | 0.00 | ||
| NetLongTermDebtIssuance | -36.22K | 0.00 | ||
| LongTermDebtPayments | -36.22K | 0.00 | ||
| InvestingCashFlow | -277.00K | -316.00K | 0.00 | 22.00K |
| CashFlowFromContinuingInvestingActivities | -277.00K | -316.00K | 0.00 | 22.00K |
| NetBusinessPurchaseAndSale | 0.00 | 22.00K | ||
| SaleOfBusiness | 0.00 | 22.00K | ||
| NetPPEPurchaseAndSale | -277.00K | -316.00K | 0.00 | 0.00 |
| SaleOfPPE | 0.00 | 0.00 | ||
| PurchaseOfPPE | -277.00K | -316.00K | 0.00 | |
| OperatingCashFlow | -15.85M | -10.75M | -8.81M | -5.19M |
| CashFlowFromContinuingOperatingActivities | -15.85M | -10.75M | -8.81M | -5.19M |
| ChangeInWorkingCapital | -6.45M | 35.83M | 843.64K | 4.33K |
| ChangeInOtherCurrentLiabilities | 68.33K | 106.06K | -76.01K | |
| ChangeInOtherCurrentAssets | 0.00 | 35.35M | 36.77K | 129.23 |
| ChangeInPayablesAndAccruedExpense | 3.02M | 1.10M | 764.32K | -218.87K |
| ChangeInPayable | 3.02M | 1.10M | ||
| ChangeInPrepaidAssets | 369.00K | -626.00K | ||
| ChangeInInventory | 0.00 | 137.61K | ||
| ChangeInReceivables | -9.84M | 0.00 | -63.51K | 161.46K |
| OtherNonCashItems | -4.25K | -408.89K | 2.91M | |
| StockBasedCompensation | 8.93M | 2.15M | 1.01M | 450.83K |
| ProvisionandWriteOffofAssets | 0.00 | -11.63K | ||
| DepreciationAmortizationDepletion | 103.00K | 88.00K | 0.00 | 0.00 |
| DepreciationAndAmortization | 103.00K | 88.00K | 0.00 | 0.00 |
| OperatingGainsLosses | 28.00K | |||
| NetForeignCurrencyExchangeGainLoss | 28.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -18.46M | -48.81M | -10.25M | -8.54M |
| CashFlowsfromusedinOperatingActivitiesDirect | -15.94M | -12.81M | -5.19M | |
| InterestReceivedDirect | 329.16K | 6.27K | 73.07K | |
| ClassesofCashPayments | -17.29M | -13.60M | -6.77M | |
| OtherCashPaymentsfromOperatingActivities | -17.29M | |||
| PaymentsonBehalfofEmployees | -13.60M | -8.97M | ||
| PaymentstoSuppliersforGoodsandServices | -6.77M | |||
| ClassesofCashReceiptsfromOperatingActivities | 1.01M | 782.38K | 1.51M | |
| OtherCashReceiptsfromOperatingActivities | 1.01M | 782.38K | 82.81K | |
| ReceiptsfromCustomers | 0.00 | 0.00 | 1.51M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IXHL
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|